8-OH-PBZI
Clinical data | |
---|---|
ATC code | none |
Identifiers | |
| |
CAS Number | 251327-33-0 |
PubChem (CID) | 10353845 |
ChemSpider | 8529297 |
Chemical and physical data | |
Formula | C15H21NO |
Molar mass | 231.34 g·mol−1 |
3D model (Jmol) | Interactive image |
| |
| |
(verify) |
8-OH-PBZI is a drug used in scientific research which acts as a potent and selective agonist for the dopamine D3 receptor.[1][2][3]
References
- ↑ Scheideler, MA; Martin, J; Hohlweg, R; Rasmussen, JS; Naerum, L; Ludvigsen, TS; Larsen, PJ; Korsgaard, N; Crider, AM; Ghosh, D; Cruse, SF; Fink-Jensen, A (1997). "The preferential dopamine D3 receptor agonist cis-8-OH-PBZI induces limbic Fos expression in rat brain". European Journal of Pharmacology. 339 (2–3): 261–70. doi:10.1016/S0014-2999(97)01372-1. PMID 9473144.
- ↑ Fink-Jensen, A; Nielsen, EB; Hansen, L; Scheideler, MA (1998). "Behavioral and neurochemical effects of the preferential dopamine D3 receptor agonist cis-8-OH-PBZI". European Journal of Pharmacology. 342 (2–3): 153–61. doi:10.1016/S0014-2999(97)01494-5. PMID 9548380.
- ↑ Malik, P; Andersen, MB; Peacock, L (2004). "The effects of dopamine D3 agonists and antagonists in a nonhuman primate model of tardive dyskinesia". Pharmacology, Biochemistry, and Behavior. 78 (4): 805–10. doi:10.1016/j.pbb.2004.05.019. PMID 15301939.
This article is issued from Wikipedia - version of the 4/2/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.